Intersect ENT

Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose, and Throat surgeons to utilize in providing improved treatment for their patients. The company was founded in 2003 by Don Eaton and is headquartered in Menlo Park, California, United States.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.

Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates

MENLO PARK, Calif.--(BUSINESS WIRE)--Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Orthofix International

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix names Thomas A. West to the Company's Board of Directors and appoints him to the Compensation and Talent Development Committee.

Orthofix Announces Appointment of Thomas A. West to Board of Directors

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?

Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?

Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes

An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.

Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track

Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Third Quarter 2021 Financial Results

Intersect ENT Reports Third Quarter 2021 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for

Baxter

Boston Scientific

Catalent

Hill-Rom Hlds

Medtronic

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intersect ENT, Inc. ("XENT" or the "Company") (XENT) relating to its proposed acquisition by Medtronic plc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT

Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.

Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top

Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion.  The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion appeared first on Pulse 2.0.

Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion

NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT) in connection with the proposed acquisition of the Company by Medtronic plc ("Medtronic") (NYSE:MDT).  Under the terms of the merger agreement, the Company's shareholders will receive $28.25 per share in cash for each share of Intersect common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.

It's official: A big peer is buying out the specialty medical device maker.

Why Intersect ENT Shot 12% Higher on Friday

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair to Intersect ENT shareholders. Halper Sadeh encourages Intersect ENT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Inters

Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT

MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic. Click here to learn how to join the action: https://www.ademilaw.com/case/intersect-ent-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic

Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates

Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.  Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures.

Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million i

Intersect ENT Reports Second Quarter 2021 Financial Results

DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.

Medtronic to Acquire Intersect ENT

Intersect ENT (NASDAQ:XENT) announces its next round of earnings this Friday, August 06. Here is Benzinga's everything-that-matters guide for this Friday's Q2 earnings announcement.

News for Intersect ENT Stock (XENT)